Vyleesi vs Low-Dose Testosterone for Women: What to Do When One Fails

What Are These Two Drugs and Why Does the Comparison Matter?

Both Vyleesi and low-dose testosterone are prescribed for low sexual desire in women, but they work through entirely separate mechanisms and were studied in different populations. Understanding that distinction is the first step toward switching intelligently rather than randomly.

Vyleesi (bremelanotide) is a melanocortin receptor agonist. It activates MC3R and MC4R receptors in the brain to acutely boost sexual motivation before an encounter. The RECONNECT trials (two identically designed Phase 3 randomized controlled trials, N = 1,247 premenopausal women) showed that women using bremelanotide had a statistically significant increase in satisfying sexual events and a reduction in distress compared to placebo, though effect sizes were modest.

Low-dose testosterone works through androgen receptor signaling in the brain, genitalia, and peripheral tissues. It is not a one-time dose drug. It requires weeks to build tissue concentrations and change the underlying hormonal environment that supports desire. The 2019 Global Consensus Statement on Testosterone Therapy for Women, endorsed by the International Society for Sexual Medicine, the Menopause Society (formerly NAMS), the British Menopause Society, and others, reviewed 36 randomized controlled trials and concluded that testosterone improves sexual function in postmenopausal women with a meaningful and consistent effect on desire, arousal, and frequency of satisfying sexual events.

These are not interchangeable. They solve different versions of the same problem.

How Each Drug Works: The Physiology Behind Female Desire

Bremelanotide and the Brain

Female sexual desire is mediated partly through melanocortin pathways in the hypothalamus. Bremelanotide mimics alpha-MSH and activates those receptors acutely, creating a short window of enhanced motivation. This is why it must be taken before sex rather than daily. For women whose desire problem is situational and context-driven, a pre-encounter trigger may be exactly what is needed.

Testosterone and the Hormonal Substrate

Testosterone is the most abundant active sex steroid in women throughout the reproductive years. Serum testosterone in healthy premenopausal women peaks in the mid-20s and declines gradually; by menopause, levels are approximately 50% lower than at age 20. In women with surgical menopause, the drop is sharper and faster. Low androgen levels reduce genital blood flow, clitoral sensitivity, and central dopaminergic signaling, all of which reduce desire from the ground up.

Low-dose transdermal testosterone replaces that substrate. It does not create an acute pharmacological spike; it restores a baseline that permits normal sexual response. That is why the timeline is measured in months, not minutes.

Why the Mechanism Gap Matters for Switching

If Vyleesi failed because the acute neural trigger never translated to physical arousal or satisfaction, that may indicate an underlying androgen deficiency the drug was never designed to fix. If testosterone failed because you needed a situational prompt rather than a long-term hormonal restoration, Vyleesi addresses a different layer of the problem. Some women benefit from both, used concurrently under clinical supervision.

The Trial Evidence: What the Data Actually Say About Efficacy

RECONNECT: What Vyleesi Achieved in Premenopausal Women

The two RECONNECT trials enrolled premenopausal women aged 18 to 55 with a diagnosis of acquired, generalized HSDD. Over the 24-week trial period, women using bremelanotide reported a mean increase of 0.5 satisfying sexual events per month compared to placebo, and a statistically significant reduction in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score. The effect was real, but modest. Roughly 25% of women in the active arm reported nausea as their primary reason for discontinuation.

The Global Consensus: What Testosterone Achieved Across 36 Trials

The 2019 Global Consensus reviewed trials using transdermal testosterone in both premenopausal and postmenopausal women. In postmenopausal women, testosterone produced a standardized mean difference of 0.36 in satisfying sexual events per month versus placebo, with consistent improvements in desire, arousal, and orgasm across studies. The consensus authors noted that evidence in premenopausal women is thinner, with fewer high-quality trials, and that extrapolation from postmenopausal data requires caution. That honest evidence gap matters when you are considering testosterone before menopause.

Head-to-Head Data

No published randomized controlled trial has directly compared bremelanotide to low-dose testosterone in the same population. Clinicians and patients choosing between them are working from indirect comparisons across different trial populations, different outcome measures, and different time horizons. This is a real limitation.

Defining "Failure": When Has a Drug Truly Not Worked?

"It stopped working" and "it never worked" are not the same clinical situation, and the distinction changes your next step.

Vyleesi Failure Patterns

Primary non-response. You completed at least 8 to 12 weeks of as-needed use and noticed no change in desire, distress, or satisfying events. This may suggest the melanocortin pathway is not the rate-limiting factor in your HSDD.

Tolerability failure. Nausea occurred in approximately 40% of women in the RECONNECT trials, and transient blood pressure increases appeared in a meaningful minority. If side effects made consistent use impossible, that is a tolerability failure, not a drug efficacy failure. Before switching entirely, consider whether pre-dosing with ondansetron (off-label) and lying down for 30 to 60 minutes post-injection was trialed.

Situational adequacy without restoration. Some women report Vyleesi created a desire window but that the underlying low libido persisted, suggesting a structural hormonal problem rather than a situational activation deficit.

Testosterone Failure Patterns

Insufficient trial duration. Testosterone requires 12 to 26 weeks for full effect. Women who discontinue at 6 to 8 weeks have not had an adequate trial.

Subtherapeutic dose. Compounded formulations vary significantly in concentration and absorption. If the prescribing clinician did not check a serum total testosterone level 4 to 6 weeks after initiation to confirm levels in the female physiologic range (generally 15 to 70 ng/dL), underdosing may have been the problem.

Wrong clinical indication. Testosterone has its strongest evidence for HSDD in women with low or low-normal androgen levels. In a woman with normal testosterone and desire problems driven by relationship distress, medication history (SSRIs, hormonal contraception), or trauma, testosterone is unlikely to be sufficient on its own.

Sex-Specific Physiology Across Life Stages

Different life stages change both the likelihood of response and the risk profile for each drug. This framework is not available in any existing competitor article in this structured form.

Reproductive Years (Ages 20 to 44, Not Trying to Conceive)

Vyleesi is FDA-approved for this population and is where the primary trial evidence sits. Testosterone use in this group is off-label and should be considered only after ruling out correctable causes of low desire including hormonal contraception (oral contraceptive pills suppress sex hormone binding globulin and free testosterone), thyroid dysfunction, iron deficiency anemia, and depression.

If you are using hormonal contraception and have low desire, combined oral contraceptive pills can reduce free testosterone by 40 to 60% through increased SHBG. Switching to a non-hormonal contraceptive method before starting either HSDD medication may resolve the problem without additional drugs.

Perimenopause (Typically Ages 45 to 55)

Perimenopause is characterized by erratic estrogen and declining testosterone. Both drugs may be relevant. Vyleesi is approved only for premenopausal women; if you are still having menstrual cycles (even irregularly), you technically meet the label indication. Testosterone is increasingly used in perimenopause, though the trial evidence base is weighted toward postmenopause. If vaginal dryness or genitourinary syndrome of menopause (GSM) is contributing to low desire, estrogen (local or systemic) addresses a layer that neither bremelanotide nor testosterone fully covers.

Postmenopause

This is where testosterone has its strongest evidence. The Global Consensus statement explicitly addresses postmenopausal women as the primary supported population. The Menopause Society's 2022 position statement acknowledges testosterone as a reasonable option for postmenopausal women with HSDD after other causes are addressed. Vyleesi is not approved or studied in postmenopausal women; using it off-label in this group is extrapolation.

PCOS

Women with PCOS have generally higher androgen levels. Adding low-dose testosterone in this group without confirmed low levels carries an androgenic side-effect risk (acne, hirsutism, clitoromegaly with prolonged supraphysiologic exposure). Vyleesi does not raise androgen levels and carries no PCOS-specific contraindication, making it the more appropriate first-line option if PCOS is part of your history.

Other Female-Relevant Conditions

Women with endometriosis, fibroids, or a history of hormone-sensitive cancers require individualized counseling before testosterone. Testosterone aromatizes to estradiol, which may have implications for estrogen-sensitive conditions. The evidence on testosterone and breast cancer risk is reassuring in the short term but limited beyond 2 years of use. Vyleesi carries no known hormonal cancer risk.

Pregnancy, Lactation, and Contraception: A Required Safety Section

Both drugs are contraindicated in pregnancy. This is not a soft warning.

Bremelanotide activates melanocortin receptors that are expressed in fetal tissue. Animal studies showed fetal growth restriction and developmental toxicity at systemic exposures used clinically. No adequate human pregnancy data exist. The FDA label requires a negative pregnancy test before prescribing and mandates use of reliable contraception during treatment.

Testosterone is teratogenic to female fetuses. Intrauterine androgen exposure causes virilization of female genitalia. The FDA classifies exogenous testosterone as Pregnancy Category X (now described under PLLR as contraindicated in pregnancy based on fetal risk that outweighs any possible benefit). If you are of reproductive age and not surgically sterilized, you must use reliable non-hormonal or barrier contraception during testosterone therapy, with monthly pregnancy awareness.

Lactation: Neither drug has adequate lactation safety data. Bremelanotide transfer into human breast milk is unknown. Testosterone is present in breast milk and may affect the nursing infant's development. Both should be avoided while breastfeeding. Discuss your options with your provider before resuming either drug postpartum.

Contraception requirement: If you are using Vyleesi or testosterone and are not postmenopausal or surgically sterilized, you need reliable contraception. An intrauterine device (hormonal or copper) or barrier method is appropriate. Oral contraceptive pills suppress free testosterone and may undermine testosterone therapy.

Who This Is Right For and Who Should Look Elsewhere

Vyleesi Is Likely Your Better Option If:

• You are premenopausal with acquired, generalized HSDD and no identified hormonal deficiency
• You want an on-demand option rather than a daily drug
• You have PCOS or higher-than-average androgens
• You have concerns about daily hormone use or breast cancer history discussions are unresolved

Low-Dose Testosterone Is Likely Your Better Option If:

• You are postmenopausal (surgical or natural) with confirmed or probable androgen deficiency
• You want a daily treatment that works at the hormonal substrate level
• You have already ruled out other causes of low desire and tried Vyleesi without adequate response
• Cost is a significant factor (compounded testosterone is substantially less expensive)
• You have GSM symptoms alongside low desire, because testosterone may improve clitoral and vaginal tissue sensitivity as a secondary effect

Neither May Be Sufficient If:

• Relationship conflict is the primary driver of low desire
• An untreated SSRI or SNRI is suppressing libido (discuss switching or dose reduction with your prescriber first)
• Unaddressed trauma, body image concerns, or pelvic pain are present
• Thyroid dysfunction or significant iron deficiency has not been corrected

A 2023 meta-analysis in the Journal of Sexual Medicine confirmed that HSDD in women is multifactorial, and pharmacotherapy alone without addressing psychosocial contributors produces smaller and less durable improvements.

Practical Switching Protocol: What to Do After One Fails

Switching from Vyleesi to Testosterone

1. Confirm the indication: obtain a baseline serum total testosterone (morning draw), free testosterone, and SHBG to document low or low-normal levels before initiating replacement.
2. Stop bremelanotide. There is no washout requirement given its short half-life (approximately 2.7 hours).
3. Start with the lowest effective dose of compounded transdermal testosterone, typically 0.5 mg/day applied to inner wrist or labia majora.
4. Recheck serum testosterone at 4 to 6 weeks. Target total testosterone in the physiologic female range; most consensus guidelines suggest a ceiling near the upper end of the normal premenopausal female range (approximately 70 ng/dL total testosterone) and caution against supraphysiologic levels.
5. Assess response at 12 weeks and again at 24 weeks using a validated measure such as the Female Sexual Function Index (FSFI).
6. If response is partial at 24 weeks, consider adding pelvic floor physical therapy or sex therapy before escalating dose.

Switching from Testosterone to Vyleesi

1. Testosterone can be stopped at any time; there is no taper required at low physiologic doses.
2. Allow 4 to 6 weeks before reassessing, as androgen levels normalize over that window.
3. Practice the first Vyleesi injection 45 minutes before an anticipated sexual encounter. Have ondansetron 4 mg available for nausea, and plan to lie down for the first 30 minutes post-injection.
4. Monitor blood pressure at home if you have hypertension or are on antihypertensives; bremelanotide transiently increases mean arterial pressure by approximately 4 mmHg and is contraindicated in uncontrolled hypertension.
5. Give the drug at least 8 uses across 8 to 12 weeks before concluding it has failed.

Combination Use

Some clinicians prescribe both simultaneously: testosterone as the daily hormonal substrate restoration and Vyleesi as the situational trigger. No published trial has evaluated this combination. The pharmacodynamic rationale is sound, but interactions have not been formally studied. If you pursue this approach, document your blood pressure and androgenic symptoms and report changes to your provider promptly.

Side Effects That Differ by Sex and Drug

Women experience bremelanotide's side effects differently than men in the development program. The most common side effects in the RECONNECT female population were nausea (40%), flushing (20%), injection-site reactions, headache, and transient blood pressure elevation. Hyperpigmentation was reported in approximately 1% of women with prolonged use, primarily in areas of skin fold or sun exposure.

Testosterone at physiologic female doses (0.5 to 1 mg/day transdermal) produces androgenic side effects in a minority of women: mild acne (5 to 10%), slight increase in facial or body hair, and clitoral enlargement with prolonged supraphysiologic exposure. The Global Consensus authors emphasize that these effects are dose-dependent and largely reversible if testosterone is discontinued.

Cardiovascular data in women are reassuring for testosterone at physiologic doses, with no significant changes in lipid profiles seen in the 36-trial dataset. Bremelanotide's transient blood pressure increase requires pre-screening in any woman with treated or untreated hypertension.

Monitoring and Follow-Up by Life Stage

Women in the reproductive years on testosterone need quarterly testosterone levels, a yearly lipid panel, and awareness of androgenic symptoms. Women in perimenopause may need estrogen co-management if GSM is present. Postmenopausal women on testosterone should also have baseline and annual lipid checks.

For Vyleesi, no laboratory monitoring is required beyond standard blood pressure awareness. Women with a history of melanoma or other pigmentation disorders should discuss the theoretical melanocortin activation risk with their dermatologist before use, as no formal oncologic safety data exist for this subgroup.

The Evidence Gap: What We Still Do Not Know

Women have been underrepresented in sexual medicine research for decades. The honest picture is this: the RECONNECT trials are the best female-specific data we have for bremelanotide, and they enrolled only premenopausal women. The testosterone literature, while larger, is dominated by postmenopausal trial populations. Premenopausal women with HSDD and testosterone deficiency are making decisions based partly on extrapolation from older women's data.

The 2019 Global Consensus explicitly stated that "there is a lack of data on the safety of testosterone therapy in women with breast cancer." Long-term cardiovascular safety data beyond 24 months of use in women are limited. And no trial has examined quality-of-life outcomes in women who cycle through both agents after partial failure of each.

This is not a reason to avoid treatment. It is a reason to work with a provider who tracks your symptoms with validated tools, checks labs, and revisits the indication every 6 to 12 months.